RSPO1

Across TCGA pan-cancer cohorts, RSPO1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RSPO1 data layer compared with 28 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher RSPO1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RSPO1 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

SCLC, LUAD, and LIHC are the cancer types where RSPO1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	II,III,IV	0.082	0.702	<.001	30	view →
LUAD	OS	Median	All	0.090	0.788	<.001	24	view →
LIHC	DFS	Median	All	0.081	0.543	.006	18	view →
COAD	OS	Median	III,IV	0.140	0.792	<.001	15	view →
SKCM	OS	Median	II,III,IV	1.000	0.299	.009	7	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RSPO1–SCLC (OS)

Open the SCLC breakdown →